Cyxone

Cyxone will work with a European organization to scale up production of the active ingredient in T20K, its experimental treatment for multiple sclerosis (MS), the company announced. The collaboration, which will cover the development of a new manufacturing method and later the…

New preclinical data continues to support the potential of Cyxone’s investigational plant-derived peptide T20K for the treatment of multiple sclerosis (MS). In a collaboration with its academic partner, the Medical University of Vienna, Cyxone has shown that a combination of T20K plus an activator of the kappa…

A small protein isolated from beetroot is able to block the activity of an enzyme called prolyl oligopeptidase (POP), which breaks down certain hormones and signaling molecules, and is thought to control the body’s inflammatory responses. According to the researchers, the discovery of this plant-derived protein may make possible…

A Phase 1 clinical trial found T20K, Cyxone’s investigational plant protein-derived treatment for multiple sclerosis (MS), to be safe and well-tolerated in healthy men, and raising the possibility that it might work at low doses, the company announced. A next step is to develop an oral formulation for the…

A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis (MS), has been dosed in a study taking place in The Netherlands, the company announced. T20K is an investigational…

Cyxone launched the first-in-human Phase 1 clinical trial assessing the effects of T20K, its new therapeutic candidate for the treatment of multiple sclerosis (MS), in healthy volunteers. The announcement came after the company received approval from the Dutch Ethics Committee and Central Commission on Research Involving Human…

Cyxone submitted an application to the Netherlands research ethics committee to start the first clinical trial in humans testing T20K, its investigational preventive treatment for multiple sclerosis (MS). Approval by the Netherlands regulating authority…

T20K, Cyxone‘s lead compound for treating multiple sclerosis (MS), seems able to prevent or slow disease progression, according to data from preclinical studies. Based on these findings, the company is confident that T20K might become a prophylactic (preventive) medication for MS in the near future. T20K is a…